Sulindac, a sulfinylindene derivative prodrug, is a nonsteroidal anti-inflammatory drug (NSAID), which approved by the FDA in 1978. Sulindac has been known for their biological activities such as analgesic, antipyretic, and anti-inflammatory activitie...
Sulindac, a sulfinylindene derivative prodrug, is a nonsteroidal anti-inflammatory drug (NSAID), which approved by the FDA in 1978. Sulindac has been known for their biological activities such as analgesic, antipyretic, and anti-inflammatory activities and its derivatives are reported as anti-cancer, anti-nociceptive activity, and antioxidant potency. Even now, research is ongoing for the expansion of their potential properties and application. Structurally, sulindac has a unique 1,2,3-trisubstituted indene skeleton bearing a synthetically formidable (Z)-benzylidene substituent at C-1, one methyl unit at C-2, and acetic acid moiety at C-3 and it contains a chiral center at the S atom. Given the interesting biological activities and an intriguing architecture, they are an unarguably attractive target for both synthetic chemists and biologists.
Herein, the efforts are described toward the synthesis of sulindac and unprecedented iso-sulindac. The key feature of a synthetic route includes the stereoselective construction of the (Z)-selective sulindac skeleton through vinylogous Stork enamine Claisen-Schmidt condensation. This synthetic strategy was expected to be applicable for the synthesis series of novel sulindac analogs.